PetMed Express Q3 2024 EPS $(0.10) Misses $(0.01) Estimate, Sales $65.317M Beat $65.000M Estimate
Portfolio Pulse from Benzinga Newsdesk
PetMed Express reported Q3 2024 earnings with a loss of $(0.10) per share, missing the $(0.01) estimate by 900%. However, their sales of $65.317M exceeded the $65.000M estimate, marking a 10.95% increase from the previous year.

April 15, 2024 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
PetMed Express missed EPS estimates by 900% but exceeded sales forecasts for Q3 2024, showing a significant sales increase from the previous year.
The significant miss in EPS estimates could negatively impact investor sentiment in the short term, potentially putting downward pressure on the stock price. However, the better-than-expected sales figures and year-over-year growth might offset some of the negative impact by indicating underlying business strength. The mixed results lead to a neutral short-term price direction score.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100